Navegar

Colección

Datos Estadísticas

Lista de

metastasis
52
"Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor–stroma crosstalk" (2018) Orozco, C.A.;Martinez-Bosch, N.;Guerrero, P.E. (...)Navarro, P. Proceedings of the National Academy of Sciences of the United States of America. 115(16):E3769-E3778
"IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity" (2018) Song, M.;Sandoval, T.A.;Chae, C.-S. (...)Cubillos-Ruiz, J.R. Nature. 562(7727):423-428
"Predictive outcomes for HER2-enriched cancer using growth and metastasis signatures driven by SPARC" (2017) Guttlein, L.N.;Benedetti, L.G.;Fresno, C. (...)Podhajcer, O.L. Molecular Cancer Research. 15(3):304-316
"Predictive outcomes for HER2-enriched cancer using growth and metastasis signatures driven by SPARC" (2017) Guttlein, L.N.;Benedetti, L.G.;Fresno, C. (...)Podhajcer, O.L. Molecular Cancer Research. 15(3):304-316
"GTSE1: A novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models" (2017) Stelitano, D.;Leticia, Y.P.;Dalla, E. (...)Schneider, C. Oncotarget. 8(40):67422-67438
"Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer" (2017) Gentilini, L.D.;Jaworski, F.M.;Tiraboschi, C. (...)Compagno, D. Oncotarget. 8(27):44654-44668
"Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer" (2017) Gentilini, L.D.;Jaworski, F.M.;Tiraboschi, C. (...)Compagno, D. Oncotarget. 8(27):44654-44668
"Turning-off signaling by siglecs, selectins, and galectins: Chemical inhibition of glycan-dependent interactions in cancer" (2016) Cagnoni, A.J.; Pérez Sáez, J.M.; Rabinovich, G.A.; Mariño, K.V. Frontiers in Oncology. 6(MAY)
"The thyroid status reprograms T cell lymphoma growth and modulates immune cell frequencies" (2016) Sterle, H.A.;Barreiro Arcos, M.L.;Valli, E. (...)Cremaschi, G.A. Journal of Molecular Medicine. 94(4):417-429
"RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors" (2016) Wu, Y.;Tedesco, L.;Lucia, K. (...)Stalla, G.K. Oncotarget. 7(36):57878-57893
"RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors" (2016) Wu, Y.;Tedesco, L.;Lucia, K. (...)Stalla, G.K. Oncotarget. 7(36):57878-57893
"Thyroid hormones and their membrane receptors as therapeutic targets for T cell lymphomas" (2016) Cremaschi, G.A.;Cayrol, F.;Sterle, H.A. (...)Barreiro Arcos, M.L. Pharmacological Research. 109:55-63
"Cytotoxic effects of natural and semisynthetic cucurbitacins on lung cancer cell line A549" (2016) Silva, I.T.;Geller, F.C.;Persich, L. (...)Simões, C.M.O. Investigational New Drugs. 34(2):139-148
"Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells" (2016) Castillo, L.F.;Tascón, R.;Huvelle, M.A.L. (...)Peters, M.G. Oncotarget. 7(37):60133-60154
"Glyco-nano-oncology: Novel therapeutic opportunities by combining small and sweet" (2016) Hockl, P.F.;Wolosiuk, A.;Pérez-Sáez, J.M. (...)Rabinovich, G.A. Pharmacological Research. 109:45-54
"Introduction to special issue: Glycans in vascular biology" (2014) Thijssen, V.L.; Rabinovich, G.A. Glycobiology. 24(12):1235-1236
"Glycans and galectins in prostate cancer biology, angiogenesis and metastasis" (2014) Compagno, D.;Gentilini, L.D.;Jaworski, F.M. (...)Laderach, D.J. Glycobiology. 24(10):899-906
"Glycans and galectins in prostate cancer biology, angiogenesis and metastasis" (2014) Compagno, D.;Gentilini, L.D.;Jaworski, F.M. (...)Laderach, D.J. Glycobiology. 24(10):899-906
"Galectin-8: A matricellular lectin with key roles in angiogenesis" (2014) Troncoso, M.F.;Ferragut, F.;Bacigalupo, M.L. (...)Elola, M.T. Glycobiology. 24(10):907-914
"Delineating the "galectin signature" of the tumor microenvironment" (2013) Compagno, D.;Laderach, J.D.;Gentilini, L. (...)Rabinovich, A.G. OncoImmunology. 2(4)
"Vascular galectins: Regulators of tumor progression and targets for cancer therapy" (2013) Thijssen, V.L.; Rabinovich, G.A.; Griffioen, A.W. Cytokine and Growth Factor Reviews. 24(6):547-558
"Vascular galectins: Regulators of tumor progression and targets for cancer therapy" (2013) Thijssen, V.L.; Rabinovich, G.A.; Griffioen, A.W. Cytokine and Growth Factor Reviews. 24(6):547-558
"Vascular galectins: Regulators of tumor progression and targets for cancer therapy" (2013) Thijssen, V.L.; Rabinovich, G.A.; Griffioen, A.W. Cytokine and Growth Factor Reviews. 24(6):547-558
"Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis" (2013) Fernández Vallone, V.B.;Hofer, E.L.;Choi, H. (...)Chasseing, N.A. Clinical and Experimental Metastasis. 30(3):317-332
"Advanced prostate cancer: Reinforcing the strings between inflammation and the metastatic behavior" (2012) Gueron, G.; De Siervi, A.; Vazquez, E. Prostate Cancer and Prostatic Diseases. 15(3):213-221
"Advanced prostate cancer: Reinforcing the strings between inflammation and the metastatic behavior" (2012) Gueron, G.; De Siervi, A.; Vazquez, E. Prostate Cancer and Prostatic Diseases. 15(3):213-221
"1,2,4-Triazole d-ribose derivatives: Design, synthesis and antitumoral evaluation" (2012) Avanzo, R.E.;Anesini, C.;Fascio, M.L. (...)D'Accorso, N.B. European Journal of Medicinal Chemistry. 47(1):104-110
"Key questions in metastasis: New insights in molecular pathways and therapeutic implications" (2011) Gueron, G.; de Siervi, A.; Vazquez, E. Current Pharmaceutical Biotechnology. 12(11):1867-1880
"Key questions in metastasis: New insights in molecular pathways and therapeutic implications" (2011) Gueron, G.; de Siervi, A.; Vazquez, E. Current Pharmaceutical Biotechnology. 12(11):1867-1880
"Emerging roles of ATF2 and the dynamic AP1 network in cancer" (2010) Lopez-Bergami, P.; Lau, E.; Ronai, Z. Nature Reviews Cancer. 10(1):65-76
"Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas" (2009) Wargon, V.;Helguero, L.A.;Bolado, J. (...)Lanari, C. Breast Cancer Research and Treatment. 116(3):449-460
"Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer" (2008) Salatino, M.;Croci, D.O.;Bianco, G.A. (...)Rabinovich, G.A. Expert Opinion on Biological Therapy. 8(1):45-57
"Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment" (2007) Croci, D.O.;Zacarías Fluck, M.F.;Rico, M.J. (...)Scharovsky, O.G. Cancer Immunology, Immunotherapy. 56(11):1687-1700
"Fibronectin is distinctly downregulated in murine mammary adenocarcinoma cells with high metastatic potential" (2006) Urtreger, A.J.;Werbajh, S.E.;Verrecchia, F. (...)Bal De Kier Joffé, E.D. Oncology Reports. 16(6):1403-1410
"Androgen receptors in human melanoma cell lines IIB-MEL-LES and IIB-MEL-IAN and in human melanoma metastases" (2002) Morvillo, V.;Lüthy, I.A.;Bravo, A.I. (...)Mordoh, J. Melanoma Research. 12(6):529-538
"Downregulation of fibronectin transcription in highly metastatic adenocarcinoma cells" (1998) Werbajh, S.E.;Urtreger, A.J.;Puricelli, L.I. (...)Kornblihtt, A.R. FEBS Letters. 440(3):277-281
"Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells" (1997) Fernanda Ledda, M.;Adris, S.;Bravo, A.I. (...)Podhajcer, O.L. Nature Medicine. 3(2):171-176
"Induccion de adenocarcinomas mamarios por progestagenos en ratones BALB/c: Progresion del tumor hormono-dependiente al autonomo" (1997) Lanari, C.;Montecchia, M.F.;Pazos, P. (...)Mounolo, A.A. Medicina. 57(SUPPL 2):55-69
"Heparin receptors in two murine mammary adenocarcinomas with different metastatic ability: relationship with growth inhibition" (1995) Bertolesix, G.E.; de Cidre, L.L.; de Lustig, E.S.; Eiján, A.M. Cancer Letters. 90(2):123-131
"Biologic, Immunocytochemical, and Cytogenetic Characterization of Two New Human Melanoma Cell Lines: IIB‐MEL‐LES and IIB‐MEL‐IAN" (1995) KAIRIYAMA, C.;SLAVUTSKY, I.;LARRIPA, I. (...)MORDOH, J. Pigment Cell Research. 8(3):121-131
"Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins" (1994) Bertolesi, G.E.; De Cidre, L.L.; Eiján, A.M. Tumor Biology. 15(5):275-283
"Establishment and characterization of a new metastatic cell line (M3MC) derived from a murine mammary tumor" (1994) Lucero Gritti, M.F.; Garcia De Palazzo, I.E.; Meiss, R.P.; Bonfil, R.D. Journal of Experimental and Clinical Cancer Research. 13(2):113-119
"Expression of gelatinise/type IV collagenase in tumor necrosis correlates with cell detachment and tumor invasion" (1992) Daniel Bonfil, R.;Medina, P.A.;Gómez, D.E. (...)Bustuoabad, O.D. Clinical & Experimental Metastasis. 10(3):211-220
"Studies to determine the possible antitumoral properties of Cobra venom and of Crotoxin Complex A and B" (1988) Baldi, A.;Mordoh, J.;Medrano, E.E. (...)Rumi, L. Medicina. 48(4):337-344
"Cancer and BCG " (1981) Rumi, L.S. Acta Physiologica Latino-Americana. 31(1):25-34